ArticleThe Journal of antimicrobial chemotherapy2021
When to change treatment of acute invasive aspergillosis: an expert viewpoint.
Article in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Diagnosis and risk factors for invasive mould disease-a round table discussion on directing antifungal therapy according to the available evidence.The Journal of antimicrobial chemotherapy · 2026Article
- Diagnosis, clinical features and survival analysis of invasive pulmonary aspergillosis among critically ill patients: a retrospective cohort study based on updated criteria.Frontiers in cellular and infection microbiology · 2026Article
- Refractory Invasive Pulmonary Aspergillosis Following Treatment of Acute Rejection in a Kidney Transplant Recipient: A Case Report.Case reports in transplantation · 2026Article
- Optimization of (Dithioperoxo)thiolate-Based Antifungal Agents for Triazole-ResistantPathogens (Basel, Switzerland) · 2025Article
- Refractory versus resistant invasive aspergillosis.The Journal of antimicrobial chemotherapy · 2025Review
- Managing Invasive Fungal Infections During Allogeneic Hematopoietic Transplantation: A 2025 Update.Mediterranean journal of hematology and infectious diseases · 2025Review
- A serum galactomannan and neutrophil-to-lymphocyte ratio-based nomogram for predicting in-hospital mortality in non-neutropenic invasive pulmonary aspergillosis.Frontiers in cellular and infection microbiology · 2025Article
- Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis.Open forum infectious diseases · 2025Article
- Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.The Journal of antimicrobial chemotherapy · 2024Article
- Clinical Mycology Today: Emerging Challenges and Opportunities.Open forum infectious diseases · 2024Review
- Invasive aspergillosis in adult patients in Australia and New Zealand: 2017-2020.The Lancet regional health. Western Pacific · 2023Article
- IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.Journal of fungi (Basel, Switzerland) · 2023Article
- Metagenomic Next-Generation Sequencing of Plasma for Diagnosis of COVID-19-Associated Pulmonary Aspergillosis.Journal of clinical microbiology · 2023Article
- InvasiveOpen forum infectious diseases · 2023Article
- Long-Term Kinetics of Serum Galactomannan during Treatment of Complicated Invasive Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2023Article
- A Whole Genome Sequencing-Based Approach to Track down Genomic Variants in Itraconazole-Resistant Species ofJournal of fungi (Basel, Switzerland) · 2022Article
- Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.Antimicrobial agents and chemotherapy · 2022Review
- Epidemiological Studies of Pan-Azole ResistantMicroorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 14 institutions in 10 countries.
Funding
Abstract
Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.